According to a newly published Future Market Insights (FMI) report, the global rare neurological disease treatment market will expand throughout the 2017-2026 forecast period. Revenues are envisaged to exceed $12bn by the end of 2026.

New drug formulations and initiatives toward improving treatment and care of patients to influence market growth

Declining blockbuster drugs have led pharmaceutical companies to keenly investigate potential new areas of research and development (R&D).

Drug manufacturers have been incentivised by the Orphan Drug Act to develop new drug formulations associated with treatment of various rare diseases such as rare neurological diseases in a bid to introduce new treatment options to the market. Regulatory advantages such as breakthrough designations, longer market exclusivity, reduced fees and tax incentives have encouraged investments in R&D of drugs related to rare neurological diseases.

The world is entering a new era where science has realised the capability of aiding development of treatment and care for patients affected with rare neurological conditions. Several initiatives are being taken to coordinate efforts of pharmaceutical companies and healthcare institutes that share similar aims to improve treatment and care for patients suffering from rare neurological diseases.

For example, the Brains for Brain Foundation, the European Brain Council, LSD Patient Collaborative and members of the pharmaceutical industry are supporting an initiative in Europe that is expected to enhance visibility, awareness and recognition of rare neurological disorders for facilitating early diagnosis. The initiative also aims to facilitate and promote collaboration and partnership between physicians, patient advocates, decision and policymakers, and researchers.

North America to lead global rare neurological disease treatment market

North America is set to lead the global rare neurological disease treatment market, with an estimated revenue share of more than 40% during 2017 to 2026. Coupled with economic and technological vigour, an increasing geriatric population in the region that is highly prone to brain-related diseases will influence demand for rare neurological disease treatment in North America.

The market revenue share of Europe and the Asia-Pacific excluding Japan (APEJ) will also remain significant. However, combined revenues from the markets in these two regions will continue to be smaller than those amassed from the market in North America. The rare neurological disease treatment market in North America and Europe will record a parallel expansion through 2026, in terms of value.

Biologics to remain preferred drug for rare neurological disease treatment

Biologics will continue to be the preferred drug for the treatment of rare neurological diseases. Revenues from sales of biologics will account for the majority of the market through the forecast period, based on drug type. However, revenues from sales of organic compounds for rare neurological disease treatment are forecast to record a relatively faster growth to 2026.

With an estimated market revenue share of nearly 60% during the 2017 to 2026 forecast period, Alzheimer’s disease will continue to dominate the market, based on indication. Revenues from treatment of this indication segment are likely to record the fast growth in the market through to 2026. Injectables will remain sought-after among modes of administration for treating rare neurological conditions.

Leading pharmaceutical companies have recently been placing more emphasis on rare diseases, with support from the government. There is a greater likelihood that effective therapeutic measures for these life threatening rare diseases will be realised in the near future.

FMI’s report identifies and tracks key players influencing expansion of the rare neurological disease treatment market, which include EMD Serono, Jazz Pharmaceuticals, Teva Pharmaceutical Industries, Johnson & Johnson, Sanofi, Medtronic, Bayer Aktiengesellschaft and Novartis.

To request a sample report, click here.

To find out more information about report methodology, click here.